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Bone marrow niche crosses paths with BMPs: a road to protection and 
persistence in CML 
 
 
Abstract 
 
Chronic myeloid leukaemia (CML) is a paradigm of precision medicine, being one of the first 
cancers to be treated with targeted therapy. This has revolutionised CML therapy and patient 
outcome, with high survival rates. However, this now means an ever-increasing number of 
patients are living with the disease on life-long tyrosine kinase inhibitor (TKI) therapy, with 
most patients anticipated to have near normal life expectancy. Unfortunately, in a significant 
number of patients TKIs are not curative. This low-level disease persistence suggests that 
despite a molecularly targeted therapeutic approach there are BCR-ABL1 independent 
mechanisms exploited to sustain the survival of a small cell population of leukaemic stem cells 
(LSCs). In CML LSCs display many features akin to haemopoietic stem cells, namely; 
quiescence, self-renewal and the ability to produce mature progeny, this all occurs through 
intrinsic and extrinsic signals within the specialised microenvironment of the bone marrow 
(BM) niche. One important avenue of investigation in CML is how the disease highjacks the 
BM, thereby remodelling this microenvironment to create a niche, which enables LSC 
persistence and resistance to TKI treatment. In this review we explore how changes in growth 
factor levels; in particular the bone morphogenetic proteins (BMPs) and pro-inflammatory 
cytokines impact on cell behaviour, extracellular matrix deposition and bone remodelling in 
CML. We also discuss the challenges in targeting LSCs and the potential of dual targeting 
using combination therapies against BMP receptors and BCR-ABL1. 
 
Discovery of Bone Morphogenetic Proteins 
 
Fundamental work carried out in the 1960s on bone regeneration by Dr. Urist lead to the 
discovery of the bone morphogenetic proteins (BMPs). His work identified the presence of 
substances naturally occurring in bone facilitating bone repair, which were named based on 
these bone inductive properties [1,2]. It was only in the 1980s, following advances in molecular 
biology technologies that BMPs were finally cloned and identified to be members of the 
transforming growth factor beta (TGF-) superfamily of cytokines [3,4]. To date more than 20 
BMP family members have been discovered, with research indicating they have extensive 
functions. Studies have shown that BMPs are crucial during embryogenesis especially for bone 
formation, with other key roles in organogenesis, angiogenesis, and haemopoiesis during 
developmental processes (reviewed by Wang et al. [5]). In adults, they are essential for bone 
regeneration and help to sustain tissue homeostasis, with deregulation of the BMP signalling 
pathway linked to a multitude of different cancer types including haematological 
malignancies [5,6]. 
 
Haemopoiesis and the bone marrow microenvironment 
 
Haemopoietic stem cells (HSCs) generate all blood lineages depending on life demands to 
maintain homeostasis within the body. They reside in a specific microenvironment - the bone 
marrow (BM) niche. The BM niche itself can be roughly subdivided into two distinct areas, 
the perivascular [7,8] and the endosteal [9] zones. Within these zones haemopoietic and other 
non-haemopoietic tissues such as osteolineage cells, sinusoidal endothelium, fibroblasts, 
Schwann cells, perivascular stromal cells, adipocytes, endothelial cells, mesenchymal stem 
cells (MSCs) and immune cells reside. The niche architecture is also supported by the 
extracellular matrix (ECM), a highly heterogeneous structure containing three classes of 
insoluble macromolecules: (a) structural proteins such as collagen, laminin and elastin, (b) 
glycoproteins including fibronectin (FN) and vitronectin (VN) and (c) glycosaminoglycans 
(GAGs) comprising keratin, hyaluronic acid and chondroitin sulfate, which display 
hydrophobic properties resulting in buffering and cell adhesion [10],[11]. The niche delivers 
signals through secreted or bound molecules, and physical cues, such as oxygen tension and 
shear stress to control cell behaviour [12]. HSCs self-renewal, proliferation, and differentiation 
into mature blood cells is orchestrated within this local microenvironment through these 
intrinsic and extrinsic cues. The perivascular zone, which contains sinusoidal endothelial cells 
and perivascular stromal cells, has been associated with more actively cycling HSCs due to its 
close proximity to the vasculature resulting in exposure to higher gradients of circulating 
chemokines, cytokines, growth factors (GF), and oxygen concentrations. The endosteal zone 
close to the inner surface of the bone cavity has been linked to HSC quiescence and self-
renewal [13], due to the more hypoxic environment and interactions with osteoblasts. HSCs 
specifically interact via N-cadherin and Jagged 1 with the osteoblasts that line the endosteal 
surface leading to activation of the Notch signalling pathway [14]. In addition, osteoblasts also 
secrete other important regulators of quiescence and HSC maintenance, such as cytokines, 
chemokines, WNTs and BMPs [15].  
 
The BM niche is a dynamic environment, with bone remodelling playing an important role in 
maintaining the integrity of the architecture. The BMP signalling pathway is essential for this 
process, with several of the BMP ligands inducing osteoblastic differentiation [5]. Several cells 
within the BM niche produce BMPs these include; stromal cells, osteoblasts, megakaryocytes, 
platelets, HSCs and major haemopoietic cells [16]. BMP2, BMP4, BMP6 and BMP7 are 
important orchestrators of this process acting on MSCs, BM stromal cells and osteoblast 
precursor cells to induce differentiation into osteoblasts [17]. Osteoblasts produce BMP2, 
BMP3, BMP4 and BMP6 [18,19], whereas HSCs and progenitor cells produce BMP2, BMP4, 
BMP6 and BMP7 [20],[21]. Once secreted these become incorporated into the ECM and can act 
in an autocrine or paracrine fashion. Several BMPs have been shown to be important in 
haemopoiesis, with BMP2, BMP4 and BMP7 involved in HSC self-renewal and maintenance, 
progenitor cell expansion and haemopoietic differentiation. In the absence of erythropoietin, 
BMP2 can stimulate HSC to commit and differentiate towards erythropoiesis [22], whereas 
BMP4 sustains stem cell maintenance and megakaryocytopoiesis by thrombopoeitin (TPO) [23], 
highlighting their role in haemopoietic commitment and homeostasis. 
 
Stem cell behaviour can also be modulated by microRNAs (miRNA). These short non-coding 
RNAs play an important role in RNA silencing and post-transcriptional regulation of gene 
expression, with several miRNAs implemented in negative modulation of the BMP signalling 
pathway (Table 1 and reviewed by Lowery et al. [24]). In the BM niche MSC have the ability 
to differentiate into adipocytes, osteoblasts, or chondrocytes with these processes induced by 
specific signalling pathways, including the Wnt and BMP pathways [25]. Silencing of the two 
key enzymes Dicer or Drosha involved in miRNA processing, in MSCs, indicates that this 
ability to differentiate is dependent on miRNAs [26]. In particular, miR-196a, miR-29b, miR-
2861, miR-3960 and miR-335-5p have been reported to enhance osteogenic differentiation [27–
30], whereas miR-143, miR-24, miR-31, miR-30c, miR642a and miR-3p regulate adipogenesis 
[31–34] Other miRNAs have been shown to negatively regulate differentiation, with miR-26a, 
miR-133, miR135, miR141 and miR-200a all reported to prevent osteogenic differentiation [35–
37]. Epigenetic changes leading to alterations in expression of miRNAs has also been linked to 
bone remodelling in osteoporosis [38], highlighting the important role miRNAs play in BM 
homeostasis. 
 
 
Table 1: MiRNA involved in regulation of the BMP pathway 
BMP2 
 
miR-140 [39] 
BMP4 
 
miR-200, miR-145, miR-196a [40–42] 
BMP7 
 
miR542-3p, miR-30a/b/c/d [43,44] 
BMPR2 miR-17-5p, miR-20a, miR-100, miR-135b, miR-302, miR-125, 
miR-153, miR-125b, miR-21 [35,45–52] 
ACVR1/ALK2 
 
miR-130a, miR-148a [53,54] 
SMAD1 
 
miR-30a/b/c/d, miR-26a, miR-155, miR-199*, miR-205 [44,55–62]  
SMAD4 
 
miR-26a, miR-205, miR-23b [56–58,62,63] 
SMAD5 
 
miR-155, miR-23b, miR-135 [35,59,60,63]  
 
 
BMP secretion and presentation within the BM niche  
 
BMPs are synthesised inside the cell as precursor proteins, consisting of three distinct domains: 
the N-terminal signal peptide essential for directing the protein to the secretory pathway; the 
pro-domain, essential for protein folding and cleavage of the secreted protein and the C-
terminal mature domain. The latter contains seven conserved cysteine residues important for 
forming the cysteine knot structure and dimerization of the mature cleaved peptide along with 
key sites for N- and O- glycosylation. Bioactivity of BMPs like many GFs is regulated post-
translationally, through these modifying events with glycosylation playing an important role in 
increasing the protein stability, half-life and receptor specificity. Proteolytic cleavage is 
essential for secretion and the signalling range of the mature dimer. BMP2 and BMP4 share 
80% homology, like other BMP family members their pro-domains are cleaved by furin at the 
consensus –R-X-X-R- site [64], uniquely BMP2 and BMP4 also contain a second site –R-X-
R/K-R- at the carboxy-terminal side of this preferred consensus sequence (Figure 1). These 
two sites have been shown to be important for altering the activity and range of the ligand with 
simultaneous cleavage at both sites maximising biological activity and increasing the 
biological range in vivo [65,66].  
 
BMPs are active either as homodimers or heterodimers with BMP2 having the potential to form 
heterodimers with either BMP6 or BMP7, whereas BMP4 forms heterodimers only with 
BMP7 [67–70]. Both precursors need to be produced simultaneously in the cell, in order for 
heterodimers to form, as this process occurs internally prior to secretion [71]. Transcriptomic 
data indicates that HSCs and progenitors express BMP2, BMP4, BMP6 and BMP7 [20],[21].  
 
Heterodimers of BMP2/7 and BMP4/7 have been shown to be 5 to 20 times more potent than 
their homodimers in osteogenic differentiation assays, and to induce bone regeneration more 
effectively than homodimers [71,72]. BMP2/6 heterodimers have also been shown to be more 
potent than their corresponding homodimers at inducing differentiation of human embryonic 
stem cells [69]. Specificity of the BMP homodimers and heterodimers is through receptor 
expression on the target cells with BMPs requiring binding to a type 1 and type 2 receptor to 
initiate signalling. Type 1 and type 2 receptors differ in their cytoplasmic regions and through 
the presence/absence of a membrane proximal serine-glycine rich sequence (GS-region) N-
terminal to the intrinsic serine/threonine kinase domain, which is only present in the type 1 
receptors. The extracellular ligand-binding domains also differ enabling ligand specificity 
(Reviewed by Yadin et al. [73]). BMP2 and BMP4 signal through the type 1 receptors 
BMPR1A/ALK3 and BMPR1B/ALK6 and the type 2 receptors BMPR2, ActRIIA, ActRIIB. 
Whereas BMP6 and BMP7 signal through type 1 receptors ACVR1/ALK2, BMPR1A/ALK3 
and BMPR1B/ALK6 and type 2 receptors BMPR2, ActRIIA, ActRIIB to activate the canonical 
BMP signalling cascade. This results in phosphorylation of the R-SMADs namely SMAD 1/5/8 
through the serine-threonine kinase activity of the type 1 receptors, pSMAD1/5/8 then 
complexes with SMAD4, translocate to the nucleus initiating expression of BMP target genes 
(Figure 1). 
 
 
Figure 1: Schematic of BMP2 and BMP4 protein structure and receptor binding. 
BMPs are synthesised inside cells as large and inactive precursors, consisting of a N-terminal signal 
peptide which directs the protein to the secretory pathway, a pro-peptide important for protein folding, 
and the C-terminal mature peptide. Following post-translational modifications, the precursors dimerize 
and the pro-domain is proteolytically cleaved by furin at Arg-X-X-Arg to generate the active 
homodimer or heterodimer. BMP2 and BMP4 also contain a second consensus furin cleavage site Arg-
X-Arg/Lys-Arg. On secretion BMPs act in an autocrine or paracrine fashion through binding to their 
specific Type I and Type II receptors. Ligand binding results in receptor dimerization, phosphorylation 
and activation of the R-SMADs (SMAD1/5/8) which complex with SMAD4, translocate to the nucleus 
and initiate transcription of target genes through binding to BMP responsive elements (BRE) in the 
promoter region. 
 
Once secreted in vivo the soluble forms of BMPs have very short half-lives of only hours, this 
is even shorter when administered systemically with clearance occurring within minutes. 
Studies indicate the activity and stability of BMPs are greatly enhanced when bound to ECM 
proteins, with bound forms of BMPs having half-lives of several months [74–76]. BMPs bind to 
the glycoprotein family of ECM, in particular FN through the GF-binding region (FNIII12-13). 
This region can sequester several GFs families including; TGF-, platelet derived growth 
factor (PDGF) and fibroblast growth factor (FGF). FN when incorporated into the ECM has a 
fibrillar conformation [77], this fibrillar FN structure enables simultaneous availability of the 
integrin-binding region (FNIII9-10) and BMP presentation enabling cell binding via integrins 
[10,11,78]. Several integrins engage with FN through FNIII9-10, these include αIIbβ3, αVβ3, αVβ6, 
αVβ1, α4β1, α5β1, and α8β1 [79], with several BM niche cells interacting with FN in this way. 
Cells, which specifically interact with FN via integrin binding include; fibroblasts, MSCs, BM 
stromal cells, HSCs and their progenitors [80,81]. The binding of GFs to the ECM in the BM 
niche enables localised, low dose administration of signals [82–84].  
 
Fitzpatrick et al. revealed insight into mechanism of BMP receptor and integrin crosstalk, and 
mechanotransduction [85]. They showed that when BMP2 and FN are combined this leads to 
bioactivity, triggering phosphorylation of SMAD1/5/8 and translocation into the nucleus. 
Furthermore, SMAD signalling was regulated by cell spreading and actin dynamics [85]. 
Additionally, oscillatory shear stress experiments in endothelial cells revealed an interaction 
between BMPR1B/ALK6 and v3 integrin through the formation of a mechanoreceptor 
complex [86,87]. Based on tissue stiffness non-haemopoietic cells can change integrin expression 
levels determining stem cell fate. Positive integrin-BMP cross-talk has been observed in 
several studies, with increases in expression of integrins in response to BMP signalling [88–91]. 
Integrin inhibition can also reduce BMP responses and SMAD transcription, without effecting 
BMP receptor binding or BMPR-integrin localization. Moreover, integrins are also able to 
repress BMP signalling [92].These findings highlight the importance of integrins regulating 
cellular responses to BMPs as both react to mechanical properties of the ECM [86]. ECM 
proteins such as FN may provide a potential new feature for GF presentation and cell 
interactions in disease modelling. Spatio-temporal controlled expression of highly abundant 
and deregulated GFs such as the BMPs in the BM microenvironment may allow us to ensure 
optimal lifespan of molecules, avoid toxic off target effects and can be potentially further 
incorporated into in vitro 3D disease models to predict in vivo responses of drug treatments in 
diseases such as haematological malignancies. In addition, research focussing on the 
development of materials which regulates the secretory profile on MSCs [82,93,94] will also help 
move research from 2D to more physiologically relevant 3D approaches. 
 
Chronic myeloid leukaemia 
 
Chronic myeloid leukaemia (CML) arises due to a genetic mutation in an HSC in the BM niche 
and accounts for about 15% of all new diagnosed leukaemia in adults [95]. CML is characterized 
by the Philadelphia chromosome (Ph+) arising from the t(9;22)(q34;q11.2) chromosomal 
translocation that generates the oncogenic fusion protein BCR-ABL1. The molecular 
consequence is a constitutively active cytoplasmic tyrosine kinase, which affects proliferation 
and myeloid cell fate, consequently overproducing immature and mature granulocytic 
cells [96,97]. CML slowly accumulates over time and proceeds in three distinct phases: chronic 
phase (CP), accelerated phase (AP) ending in a terminal blast crisis if untreated. There are 
currently 4 tyrosine kinase inhibitors (TKIs) used as frontline therapy (imatinib, nilotinib, 
dasatinib, and bosutinib), designed to block the kinase activity of ABL1. However, TKIs are 
not curative and low-level disease persistence suggests that despite a molecularly targeted 
therapeutic approach there are BCR-ABL1 independent mechanisms exploited to sustain the 
survival of a small cell population of leukaemic stem cells (LSCs). LSCs share many features 
with HSCs and are able to self-renew, as well as produce leukaemic cells. They are able to 
rebuild and control their microenvironment, creating a more specialised niche for their needs 
in which they can persist and resist TKI treatment based on stem cell-niche cross talk. 
Therefore, TKIs fail to eliminate these cells even in patients showing complete cytogenetic 
remission (CCyR) [98,99]. Single cell transcriptomic analysis discovered sub-populations of 
therapy-resistant cells that are not apparent in bulk cell-population analysis[100]. These cells are 
resistant to therapy, meaning when TKI treatment is stopped the disease is likely to return. LSC 
subpopulation heterogeneity could drive resistance and is dependent on the cues offered by the 
microenvironment. Clinical trials exploring discontinuation of treatment in patients with major 
molecular response (MMR, i.e. those that achieve a 4 log or greater reduction of quantitative 
BCR-ABL1 expression from standardised baseline over a prolonged period) have revealed 
disease-persistence through quiescent LSCs [101,102]. After treatment withdrawal approximately 
30-40 % of patients experienced a molecular relapse defined as the loss of MMR [101,102].  
 
Role of the BMP pathway in sustaining CML LSC in the BM niche 
 
Recent studies indicate both an intrinsic and extrinsic deregulation of the BMP pathway in 
CML patients, with alterations most prevalent in TKI resistant patients [103–105],[106]. 
Laperrousaz et al. revealed deregulation of BMPR1B/ALK6 and downstream signalling 
elements, such as SMAD1, SMAD4, SMAD5, SMAD6, ID2 and RUNX1 in CP CML patients 
compared to healthy controls [103]. Deregulation of the pathway was also confirmed by Toofan 
et al. who showed that differential expression of BMP pathway genes such as ACV1C, INHBA, 
SMAD7, SNAIL1 and SMURF2 could be linked to treatment response [105]. BMPR1B/ALK6 
was identified as the main driver for myeloid progenitor expansion with BCR-ABL1 oncogene 
being sufficient to increase BMPR1B/ALK6 cell membrane expression in CML [103]. 
Moreover, a higher abundance of BMP2 and BMP4 in the BM plasma of CP-CML patients at 
diagnosis was determined compared to normal donors. BMPR1B/ALK6 high cells responded 
to BMP2 and BMP4 stimulation with an increase in progenitors but the same was not observed 
in BMPR1B/ALK6 low cells [103]. However, only BMP4 supplementation expanded stem cell 
numbers, and genotypically all expanded cells were Ph+ [103]. On a molecular level, BCR-ABL1 
overexpression increased BMPR1B/ALK6 surface expression [103], but BCR-ABL1 expression 
itself was not affected by BMP2 or BMP4 stimulation [104]. Conversely, TWIST-1 a 
transcription factor involved in LSC resistance [107], was overexpressed upon BMP exposure. 
TWIST-1 overexpression was reported by Wang et al., to support stem cell growth, drug 
resistance, tumour-initiating properties and to increase clonogenic capacities in acute myeloid 
leukaemia [108]. TWIST-1 increased under BMP2 and BMP4 stimulation despite imatinib 
treatment, indicating BMPR1B/ALK6+ cells may be resistant due to TWIST-1 mediated 
upregulation [104]. On the clinical site, 40 % of newly diagnosed patients display higher 
BMPR1B/ALK6 levels [104]. Upon imatinib treatment BMPR1B/ALK6 expression increases, 
without expression modification in healthy controls, which could demonstrate a subselection 
of BMPR1B/ALK6+ immature cells in vivo during TKI treatment. Furthermore, 
BMPR1B/ALK6 high cells survived TKI treatment better than BMPR1B/ALK6 low cells. 
Higher BMPR1B/ALK6 transcript levels were only observed in BM samples whereas MNC 
from peripheral blood displayed normal amounts. These findings indicate that BMP ligands 
and signalling play an important role in CML pathogenesis and CML disease persistence. 
 
 
Remodelling of the BM niche in CML 
 
In CML several features of BM remodelling have been reported including increased BM 
vascularity and fibrosis 45,46,[111]. Fibrosis is a common complication of myeloproliferative 
neoplasms (MPNs) and can lead to myelofibrosis, extramedullary haemopoiesis, and 
ultimately disease progression. In BCR-ABL1 negative MPNs, myelofibrosis is driven by the 
malignant stem/progenitor clone and an increase in megakaryocytes in the BM leading to a 
pro-inflammatory phenotype [112]. In CML, patients with high grade fibrosis at diagnosis 
reportedly have a poorer prognosis with a significant reduction in numbers reaching MMR 
following TKI treatment [113,114]. Fibrosis is thought to be a secondary event in CML caused in 
response to the cytokines released by the malignant stem/progenitor cells. It is known that 
cytokines form a pro-inflammatory environment during CML development, providing an 
advantage to LSCs by helping mediate TKI resistance [12,115,116]. In CML there is evidence for 
increased expression of several cytokines including FGF, hepatocyte growth factor (HGF), IL-
1, IL-6, IL-8, PDGF, TGF-β, tumour necrosis factor-α (TNF-α), vascular endothelial growth 
factor (VEGF), BMP2 and BMP4 [103,117–124] .  
 
Increased levels of FGF, IL-6 and VEGF have been linked to promoting angiogenesis. IL-6 
levels in CML patients were found to directly correlate with BM angiogenesis and to increase 
during disease progression (reviewed by Valent et al. [123]). Moreover, blockage of IL-6 activity 
can restore treatment sensitivity [120,121]. Furthermore, BCR-ABL1 expression increases VEGF 
production in CML cells, with high VEGF levels correlating to a decreased survival rate 
(reviewed by Valent et al. [123]). Another common feature of CML is high numbers of 
megakaryocytes in the BM [125]. In MPNs neutrophils and megakaryocytes have been reported 
to undergo emperipolesis, whereby neutrophils deliver their enzymes leading to the release of 
cytokines such as TGF-β, PDGF and FGF by the megakaryocytes. Fibrosis is primarily due to 
a TGF-β induced production of total collagen, deposition of laminin and adhesive 
glycoproteins (VN, FN and tenascin) in the BM niche by MSC, megakaryocytes and 
osteoblasts. BMPs have also been linked to aberrant BM matrix homeostasis in myelofibrosis 
with BMP1, BMP6, BMP7 and BMPR2 significantly elevated as the disease progresses. BMP 
molecules are expressed by non-leukaemic cells, such as stromal cells, megakaryocytes, and 
platelets [23,103] as well as through an autocrine loop by TKI resistant CD34+ leukaemic cells 
themselves [104]. Long term pressure of TKI treatment increases the secretion of BMP2 by 
MSCs in CML with MSCs of resistant patients producing higher amounts of BMP4 compared 
to healthy cells [104,126]. In fibrosis BM stromal cells and megakaryocytes have been shown to 
be the predominant source of BMP1, which then activates the latent form of TGF-. Fibroblasts 
then secrete BMP6 in response to the higher levels of TGF- in the niche [127]. Expression of 
PDGF is also associated with BM fibrosis especially in accelerated phase and blast crisis CML 
[123,128]. This high GF gradient in the BM niche then stimulates fibroblasts to cause fibrosis and 
endothelial cells to cause neoangiogenesis (Figure 2).  
 
 
 
Figure 2: Bone marrow niche remodelling in CML. 
HSCs interact with and are regulated by an intricate and vibrant multicellular BM niche. They have 
close anatomical and functional relationships with cells in the BM. The players in the BM niche include 
GFs such as the morphogenetic proteins, chemokines and cytokines, the ECM, adhesion factors, and 
the sympathetic nervous system. BMP ligands are highly abundant in the CML BM microenvironment 
and can be produced by osteoblasts, MSC, endothelial cells, major haemopoietic cells, LSC and 
progenitor cells by an autocrine loop. This coupled with the increased levels of pro-inflammatory 
cytokines released by LSC and progenitor cells can lead to bone remodelling, fibrosis and 
neoangiogenesis in CML.  The release of BMPs and pro-inflammatory cytokines also contributes to 
LSC’s resistance to TKIs. Interactions between LSCs and osteoblasts favours quiescence, the higher 
numbers of osteoblasts generated by bone remodelling in response to these changes in GF levels in 
CML is therefore likely to favour LSC self-renewal and survival by supporting a quiescent stage. 
 
Another process linked to myelofibrosis is bone remodelling with increased numbers of 
osteoblasts resulting in osteosclerosis and neoangiogenesis as the disease progresses. High 
levels of IL-1 have been linked to inhibiting osteoclastogenesis [129], this is through IL-1 
stimulating production of osteoprotegerin by stromal and endothelial cells. High 
osteoprotegerin can lead to unbalanced osteoblast proliferation. In CML BM, monocytes and 
endothelial cells reportedly express high levels of IL-1 with higher than normal levels of the 
cytokine detected in BM aspirates [122]. These observations coupled with the increase levels of 
BMP2 and BMP4 reported in CML suggest that osteoblastogenesis is favoured over 
osteoclastogenesis. Higher osteoblast numbers would favour LSC self-renewal and survival in 
CML. Furthermore, several of these cytokines confer growth advantage to LSCs including 
TGF- [130] BMP2 and BMP4 [103,104,131–133]. CML LSCs demonstrate high levels of IL-1R 
expression with IL-1 potentiating TKI resistance whereas inhibiting the pathway is able to 
restore TKI sensitivity [122]. Moreover, BMP4 increases haemopoietic progenitor adhesion to 
the stroma, leading to controlled stem cell behaviour [23,91,126] . BMPR1B/ALK6 signalling 
pathway also allows long-term HSC adhesion to spindle-shaped N-cadherin CD45.2 
osteoblastic (SNO) cells by the molecules N-cadherin and beta-catenin and regulates niche 
size[134] [135]. 
 
GF secretion and signalling in the BM niche can alter in response to intrinsic and extrinsic 
factors to meet the haemopoietic demands of the body. Through tight regulation this process 
sustains homeostasis over time. If the dynamics of this environment alters due to a 
haematological malignancy, then this balance will be perturbed resulting in remodelling of the 
niche due to alterations in GF levels impacting on cell behaviour. Data suggests that the long 
latency in CML development and the alteration in the GF levels in the BM niche results in an 
environment whereby the altered secretome leads to changes in the BM matrix, cell numbers 
and overall dynamics of the BM niche. 
 
Targeting the BMP pathway 
When considering CML therapy we need to take into account GF signalling in the BM niche 
as this is tightly connected with kinase phosphorylation and LSC cell survival, thereby giving 
us a potential platform for drug targeting. Data from our group indicates that combinatorial 
treatment of a BMP receptor inhibitor and a TKI is a promising avenue for the future treatment 
of CML. Our results showed that dual targeting of BMP pathway signalling and BCR-ABL1 
leads to altered cell cycle gene transcription, irreversible cell cycle arrest, along with increased 
apoptosis compared to single treatments. More importantly, inhibition resulted in fewer cell 
divisions, reduced numbers of CD34+ cells and colony formation from CML patient samples 
compared with healthy controls [105] . These promising results suggest that this approach 
warrants further investigations. There are several avenues to explore to target the BMP pathway 
in the future (Figure 3). At present, there is powerful toolbox of small molecule inhibitors or 
neutralizing antibodies inhibiting a handful of ligands (BMP2, BMP4, BMP6, BMP7, and 
BMP10), and receptors (ACVRLI /ALK1, ACVR2A, and ACVR2B), as well as the ability to 
use recombinant proteins of the antagonists (noggin and gremlin) [24,136,137]. Firstly, 
BMR1B/ALK6 receptor binding sites can be directly blocked by inhibitors such as 
dorsomorphin[138] or LDN-193189 [24]. Secondly, secreted BMP molecules by leukaemic or 
non-leukaemic cells can be inactivated by trapping them using small antagonistic molecules, 
such as Noggin, Chordin or Gremlin to prevent binding with their cognate receptors [24,139], or 
BMP ligand expression can be silenced by RNA interference [137]. Newly designed analogues 
are constantly being developed and screened to make more specific compounds, such as 
K02288 [140] or LDN-212854 [141]. They are both similar to LDN-193189, however they display 
higher selectivity against ACVR1/ALK2 and are very effective at low concentrations. 
Furthermore, K02288 specifically inhibits BMP-induced SMAD pathway without effecting 
TGF- signalling. Chemical alterations of already known compounds provide a powerful tool 
to investigate BMP signalling in more depth and is the basis for pre-clinical drug development 
[140,142]. Another route is the delivery of recombinant BMP antagonists via gene transfer or 
exogenous products to increase extracellular antagonist concentrations [137] [24]. Alternatively, 
BMP-BMPR interaction can be mimicked by using decoy receptors, which comprise only the 
receptor binding domain of individual BMP receptors and thus can enhance particular binding 
affinity and decreases signalling [24]. However, BMPs exist both in solution and bound to ECM, 
which presents it to surrounding cells and can also sequester BMPs when needed. Sequestration 
of BMPs by ECM can prevent BMP receptor binding due to conformational changes [143]. 
These two modes of presentation can distinctly regulate cell behaviour and their role in the BM 
microenvironment, and need to be taken into account when inhibiting BMP signalling [85].  
 
Deregulation of BMP signalling in CML upon TKI pressure needs to be further investigated in 
the future with the aim to identify key downstream target genes and to understand the crosstalk 
between BMP receptors, integrins and the ECM within the BM niche. Preliminary experiments 
have shown that combinatorial treatment of TKIs along with BMP receptor antagonists are a 
promising therapeutic approach to target the deregulated intrinsic and extrinsic BMP pathway 
in CML [105].  
However, many current BMP receptor inhibitors display off target effects and often inhibit 
more than one type of receptor. Therefore, new and more specific antagonists or derivatives of 
already known compounds need to be developed. Companies such as M4K Pharma have been 
connecting scientists with different expertise across the globe in an open science policy to fast 
and efficiently develop new ALK inhibitors with the hope to effectively treat diffuse intrinsic 
pontine glioma (DIPG) and other BMP driven diseases. Future studies need to investigate not 
only combination therapy of TKIs and BMP antagonist, but also the physical cues and 
presentation of GF by the ECM in the BM microenvironment, as these are used by the LSCs 
to circumvent treatment effects and promote LSC self-renewal and persistence. In order for 
promising compounds to be developed clinically robust pre-clinical testing is required in vivo. 
Several pre-clinical mouse studies investigating the deregulation of BMP signalling in other 
diseases have proven the safety and efficiency of BMP pathway inhibitors. Dorsomorphin and 
LDN-193189 increased cancer survival and decreased cell viability in a dose-dependent 
manner in a mouse intraperitoneal xenograft model of epithelial ovarian cancer. In a mouse 
model of fibrodysplasia ossificans progressive (FOP), LDN-1893180 dramatically reduced 
heterotopic ossification [6,144]. Furthermore, spontaneous mouse models of metastatic breast 
cancer displayed a reduction in primary tumours burden using DMH1, an effective inhibitor of 
ACVRLI/ALK1, ACVR1/ALK2 and BMPR1A/ALK3 [6,145]. Mouse model studies in AML 
using subcutaneously implantable materials with human MSCs are able to create a humanized 
microenvironment with niche properties useful for haemopoietic studies. Adoption of similar 
platforms would be useful to study BMP pathway inhibitors as well as the expression of 
specific BMPs by MSCs [146] [147]. Such approaches could be employed to investigate targeting 
of the BMP pathway in CML in the future. 
 
Table 2: BMP pathway inhibitors 
Natural 
Antagonists 
Target/mode of action Reference(s) 
Chordin Inhibition of BMP and BMP-receptor interaction; interacts 
with BMP2, BMP4, BMP5, BMP6, BMP7 but not INHBA 
 
[24,139,148]  
 
Noggin Blocks binding of BMPs to their receptor; binds to BMP2, 
BMP4, BMP5, BMP6, BMP7, BMP13, and BMP14 
 
[139,149–151]  
Gremlin Inhibits predominantly BMP2 and BMP4; less potent to 
BMP7 
 
[139,151–154] 
Follistatin Blocks activin receptor interaction and forms an inactive 
BMP and BMP receptor complex; binds BMP2, BMP4, 
BMP6 and BMP7 (but BMP2,4,6 with low affinity); does 
not inhibit BMP4 binding to its receptor, instead it forms a 
[149,155–158] 
non-functional BMP-BMP receptor complex; can form an 
inactive complex with BMP15 
 
Cerberus Direct binding to Nodal, Wnt, and BMP4 through distinct 
domains  
 
[151,155,159,160] 
Usag1 Binds and inhibits BMP2, BMP4, BMP6 and BMP7, also 
Wnt antagonist 
 
[151,155,161] 
Sclerostin 
(SOST) 
Direct binding to BMP5, BMP6 and BMP7 with high 
affinity and to BMP2 and BMP4 with a lower affinity; only 
inhibits BMP6 and BMP7 activities; prevents binding of 
BMPs to their receptor 
 
[155,159,162,163] 
Coco Binds and inhibits BMP4 [155]  
 
PRDC/GREM2 Efficiently inhibits BMP2 and BMP4, and weakly inhibits 
BMP6 and BMP7; however, heparin interferes with 
binding of PRDC to BMP-2  
 
[151,155,164,165] 
 
DAN/NBL1 Directly binds and blocks BMP2, BMP4 and BMP7 
 
[151,155,166] 
Twisted 
Gastrulation 
(TWSG1) 
Promotes and inhibits BMPs; binds BMP2, BMP4, and 
BMP7, but only inhibits BMP7; forms a ternary complex 
with BMPs and chordin to enhance the inhibitory activity 
of chordin on BMP 
 
[151,155,167,168] 
Crossveinless 
2/BMPER 
Binds BMP2, BMP4, BMP6, BMP7, BMP9; masking 
BMP2- receptor type I and type II binding interfaces in 
BMP2; inhibit BMP2- and BMP4-dependent osteoblast 
differentiation 
  
[155] [169] [169] 
 
Brorin/Vwc2 
and Brorin-like 
Inhibit BMP2 and BMP6 [139,170,171] 
Tsukushi BMP antagonist that acts in cooperation with Chordin; 
binds BMP4  
 
[139,172,173] 
BMPR 
inhibitors 
  
Dorsomorphin Inhibition of ACVR1/ALK2, BMPR1A/ALK3, and 
BMPR1B/ALK6 – BMP type I receptors; significant off 
target effects (VEGF-2/KDR and PDGFR-); pre-clinical 
study in epithelial ovarian cancer; dorsomorphin is still in 
preclinical development stage and no clinical trial is 
ongoing currently 
 
[6,24,174–176] 
LDN-193189 
(LDN) 
Targets ACVRLI/ALK1, ACVR1/ALK2, BMPR1A/ALK3 
and BMPR1B/ALK6; more potent (ca 100fold) and 
metabolic stable than dorsomorphin; less off-target effect 
[6,24,140,176,177] 
(ca 10 fold to PDGFR-); only weakly inhibits 
ACVR1B/ALK4, TGFBR1/ALK5, and ACVR1C/ALK7; 
off target effects such as BMPR2 and TGFBR1/ALK5; 
Ongoing research further develops LDN-193189 in 
preparation for clinical testing in patients with FOP and 
autoimmune disease 
 
LDN-212854 Preferred selectivity for ACVR1/ALK2 in preference to 
ACVRLI /ALK1 and BMPR1A/ALK3 compared to LDN-
193189; reduced off target effects compared to LDN; 
ongoing research in preparation for clinical testing in 
patients with FOP 
 
[6,24,141,178] 
LDN-214117 Higher selectivity for ACVR1/ALK2 than LDN-193189 or 
K02288 and lower cytotoxic profile; no clinical trials 
 
[6,24,179] 
1LWY Enhanced selectivity for ACVR1/ALK2, reduced off-target 
effects compared to dorsomorphin and LDN, also selective 
for BMPR1A/ALK3 and BMPR1B/ALK6; no clinical 
trials 
 
[24,180] 
DMH1 Dorsomorphin analogue; highest selectivity for BMP 
pathway; very selective for ACVR1/ALK2; also selective 
for BMPR1A/ALK3, ACVRLI/ALK1, and 
BMPR1B/ALK6; no activity against TGFBR1/ALK5; no 
clinical trials 
 
[6,24,181]  
DMH2 Dorsomorphin analogue; pan type-inhibitor selective for 
BMPR1B/ALK6, BMPR1A/ALK3 and ACVR1/ALK2; off 
target effects such as ACVR1B/ALK4, TGFBR1/ALK5 
and BMPR2; no clinical trials 
 
[6,24,181] [182] 
DMH3 Dorsomorphin analogue; reduced off targets effect 
compared to dorsomorphin and LDN; no clinical trials 
 
[6,24,181]  
ML347 Enhanced selectivity for ACVRLI/ALK1, ACVR1/ALK2; 
can discriminate between type 1 BMP receptors: >300-fold 
selectivity for ACVR1/ALK2 compared to 
BMPR1A/ALK3; reduced off target effect compared to 
dorsomorphin and LDN; no clinical trials 
 
[6,178,183]  
VU5350 Pan-type 1 BMP receptor inhibitor, targeting 
BMPR1A/ALK3, ACVR1/ALK2 and BMPR1B/ALK6, off 
target effects such as BMPR2; no clinical trials 
 
[24,180]  
K02288 Inhibits BMP-stimulated phosphorylation of SMAD1/5/8 
without affecting TGF- signalling; no clinical trials 
 
[6,140] 
PF-03671148 TGFBR1/ALK5 inhibitor, also shown to be selective 
against ACVRLI /ALK1; no clinical trials 
[142,184] 
 
PF-03446962 Inhibitor of ACVRLI /ALK1; In several clinical trial: 
patients with urothelial cancer, advanced malignant pleural 
mesothelioma and hepatocellular carcinoma 
 
[185–187] 
Compound 19 TGFBR1/ALK5 inhibitor; no clinical trials 
 
[142,188,189] 
Quinazolinone 
1  
Inhibition of ACVR1/ALK2 kinase domain; no clinical 
trials 
 
[142] [190] 
 
Neutralizing 
antibodies and 
extracellular 
domains 
(ECD) 
 Reviewed in 
[24] 
Anti-BMP2 Ab Blockage of BMP2 
 
[191,192] 
Anti-BMP4 Ab Blockage of BMP4 
 
[192–194] 
Anti-BMP6 Ab Blockage of BMP6 
 
[195–197] 
Anti-BMP7 Ab Blockage of BMP7 
 
[198,199] 
Anti-BMP10 
Ab 
Blockage of BMP10 
 
 
[200] 
Anti-ALK1 Ab Competes highly efficiently with the binding of the 
ACVRLI /ALK1 ligand BMP9 and TGF-β to 
ACVRLI/ALK1 
 
[201] 
BMPR1a-ECD Inhibition of action of GDF9 and BMP15 
 
[202] 
Hemojuvelin-
ECD 
Inhibits BMP6 
 
[195,203,204] 
Dragon-ECD Potent inhibitor of BMP2 or BMP4 but a less potent 
inhibitor of BMP6 
 
[196] 
ALK1-ECD Binds with high affinity to BMP9 and BMP10; currently in 
clinical trial as cancer therapy 
 
[205–209] 
ALK3-ECD prevent receptor-mediated signalling by sequestering BMP 
ligands; bind BMP2/4 specifically and with high affinity 
and prevent downstream signalling 
 
[210–213] 
ACVR2A-
ECD 
Inhibits BMP10 and BMP11 [214] 
ACVR2B-ECD Sequesters activins 
 
[214,215] 
 
 
 
 
Figure 3: Current approaches to inhibit BMP/SMAD and BCR-ABL1 signalling. 
There are several mechanisms that can be employed to prevent BMP pathway signalling and 
upregulation of early response genes, such as RUNX2, ID1-3 or TWIST-1 through BCR-ABL1 
dependent and independent mechanism. The early response gene expression of ID1-3 can be enhanced 
through BCR-ABL1 mediated STAT and SRC signalling with the genes having a SRC-responsive 
element (SRE) upstream of the translational start site. The same set of genes can be further activated 
through BMP/SMAD signalling that regulates gene expression through a BMP responsive element 
(BRE) in its promoter. Furthermore, BMPs as well as integrins react to mechanical properties of the 
ECM and together can form a mechanoreceptor complex (BMPR1B/ALK6 and v3). The expression 
of integrins can increase in response to BMP signalling and integrin inhibition can reduce BMP 
responses and SMAD transcription. Inhibition or promotion of BMP signalling via integrins highlights 
the importance of mechanotransduction and thus activation of survival pathways. BMP molecules can 
be trapped by antagonists such as Noggin (NOG) or Chordin (CHRD) to prevent BMPR binding or 
BMPR inhibitors can block the binding site at the receptor itself. Furthermore, decoy receptors with 
enhanced binding affinity are able to mimic BMP-BMPR interaction and decrease signalling. This 
combined with TKIs against ABL1 and SRC to target BCR-ABL1 signalling is a promising avenue to 
explore in CML. 
 
 
 Importance of the field: CML patient outcome has improved significantly since the 
introduction of TKIs, however resistance mechanism and permanent reliance of 
patients on treatment highlights the need to explore new therapeutic pathways. Intrinsic 
and extrinsic deregulation of the BMP pathway has been shown to be most prevalent in 
TKI resistant patients. Understanding GF signalling in the BM niche, particularly BMP 
pathway deregulation and how this cross talks with BCR-ABL1 to mediate downstream 
effects on genes involved in self-renewal, proliferation and differentiation can open 
potential avenues for exploring new treatment strategies to improve patient outcomes 
in the future. 
 
 Summary of current thinking: Higher abundance of BMP2 and BMP4 in CP-CML 
patients at diagnoses, persistence of BMPR1B/ALK6 high cells following TKI 
treatment and differential expression of BMP pathway related genes in CML indicates 
an important role for BMP pathway signalling in the pathogenesis of the disease. A 
variety of cells in the BM including stromal cells, megakaryocytes, platelets, 
osteoblasts and HSCs are able to produce BMP ligands, which in haematological 
malignancy can be perturbed and result in remodelling of the niche. Adverse amounts 
of BMPs impact on LSC behaviour such as self-renewal, proliferation and dormancy. 
Furthermore, the altered secretome can lead to changes in ECM composition, the 
balance in cell numbers and ultimately the dynamics within the niche. Bone 
remodelling itself plays an essential role in maintaining the niche’s integrity and 
architecture with overexpression of BMP ligands such as BMP2, BMP4, BMP6 and 
BMP7 inducing osteoblastic differentiation, which could be important for sustaining 
LSCs persistence following TKI treatment. 
 
 Future directions: When considering new treatments, it is necessary to take into 
account BM niche remodelling, including changes in GF levels and signalling 
combined with the ECM composition. One avenue to explore is the important cross-
talk between BMP/SMAD and BCR-ABL1 signalling in CML (Figure 3). SRC is a key 
downstream kinase activated via BCR-ABL1 signalling. BMP signalling can cooperate 
with SRC to activate downstream targets especially the ID family of early transcription 
factors. ID genes support cell cycle progression, self-renewal and early differentiation 
of stem cells and contain both SRC responsive element (SRE) and BMP responsive 
element (BRE) upstream of the promoter region. Targeting both of these mechanisms 
using a dual ABL1/SRC TKI combined with inhibiting key ALKs (ACVR1/ALK2, 
BMPR1A/ALK3 and BMPR1B/ALK6) warrant further investigation in CML. 
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